Drug Profile
PF 6743649
Alternative Names: PF-06743649; PF6743649Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gout
Most Recent Events
- 10 Feb 2015 Pfizer terminates enrolment in phase I trial in Healthy elderly volunteers in USA (NCT02170012)
- 01 Dec 2014 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT02151617)
- 10 Nov 2014 Pfizer terminates a phase I trial in Gout in USA (NCT02187029)